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Abstract: Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor 
with many cardiovascular (CV) indications. The objectives of this article are to review the 
pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical 
relevance in cardiovascular medicine. Various populations have been studied in large clinical 
trials including patients with congestive heart failure (CHF) after an acute myocardial infarction 
(AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and 
prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left 
ventricular function soon after AMI signiﬁ  cantly reduced the risk of overall mortality, mortality 
from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril 
after AMI complicated by left ventricular dysfunction appears to be of considerable importance in 
patients with diabetes mellitus by saving lives and substantially reducing the risk of progression 
to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk 
patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum 
of patient populations studied, the well established dosage and its proven trough-to-peak effect 
ratios permitting a safe once-a-day administration.
Keywords: trandolapril, angiotensin converting enzyme inhibitors, hypertension cardiovascular 
diseases, diabetic nephropathy
Introduction
In the early 1970s, a Brazilian biologist noticed that the venom of the pit viper 
(Bothrops jararaca) was able to potentiate the action of bradykinin. This discovery led 
to the development of teprotide. This nonapeptide is a potent angiotensin converting 
enzyme (ACE) inhibitor and causes hypotension in vivo. Further research expanded 
the knowledge of ACE inhibition and led to the introduction of captopril in 1975, the 
ﬁ  rst orally active ACE inhibitor (Aurell 1998; Hedner et al 1998).
Trandolapril is an orally administrated ACE inhibitor that has been used for over two 
decades in the management of various cardiovascular disorders. This review will brieﬂ  y 
describe the pharmacodynamic and pharmacokinetic properties of trandolapril, then 
discuss in more detail its use in patients with congestive heart failure (CHF) after acute 
myocardial infarction (AMI), in diabetic patients, in patients with arterial hypertension 
(HTN) and stable coronary disease, and in the prevention of proteinuria.
Pharmacodynamic and pharmacokinetic properties
Trandolapril is a non-sulfhydryl prodrug that is rapidly hydrolyzed in the liver to the 
active diacid compound, trandolaprilat. Trandolaprilat has a high binding afﬁ  nity for 
ACE and the drug concentration required to inhibit ACE activity by 50% (IC50) is 
less than that of enalaprilat, captopril and quinaprilat, and similar to that of ramiprilat 
(Wiseman and McTavish 1994). Maximal ACE inhibition after repeated doses occurs 
at 3 hours in younger patients and at 1.5 hours in older patients (Arner et al 1994). Vascular Health and Risk Management 2008:4(6) 1148
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Trandolapril is a highly lipophilic drug, which may facilitate 
tissue ACE inhibition with potential effects in cardiovascular 
remodeling (Wiseman and McTavish 1994). The main 
pharmacodynamic effects of trandolapril are achieved by 
a reduction in plasma angiotensin-II levels. This leads to 
a reduction in peripheral vasoconstriction, blood pressure, 
total peripheral resistance, and decreased sodium and water 
retention by the kidney. ACE inhibitors increase bradykinins 
production, which explains their main side effect of dry 
cough (Figure 1).
Several small size non-blinded pharmacodynamic studies 
were done to assess cardiovascular effects of trandolapril. In 
one study of 27 hypertensive patients aged 18–75, plasma 
norepinephrine levels were either statistically unchanged or 
decreased (17%–32%). In this trial, a single-blind, 2-week 
placebo run-in period was followed by 2 double-blind cross-
over periods, each of 4 weeks, when patients were random-
ized to receive either 2 mg trandolapril once daily or matching 
placebo (Petrie et al 2000). In another trial of heart failure 
patients with NYHA class III or early class IV symptoms, 
neurohumoral activation was attenuated and plasma epineph-
rine decreased (32%) (van der Ent et al 1998). All patients 
had heart failure symptoms combined with a cardiothoracic 
ratio   0.50 on chest x-ray and/or left ventricular (LV) ejection 
fraction   0.35 and/or capillary wedge pressure  15 mmHg, 
and previous treatment with ACE inhibitors was stopped 
for at least 1 week before (van der Ent et al 1998). 
Cardiac performance indices (LV stroke work and volume) 
were also signiﬁ  cantly increased (van der Ent et al 1998). 
In other small studies, signiﬁ  cant reductions were observed 
in total peripheral resistance (13%–23%), LV hypertrophy 
and remodeling (LV mass index 24%), end-systolic stress 
(8%–12%), pulmonary capillary wedge pressure (43%–45%), 
and pulmonary artery pressure (29%) (De Luca et al 1992; 
Guller et al 1993; van der Ent et al 1998).
The bioavailability of trandolapril is not affected by 
concomitant food intake. One third of the drug is excreted in 
the urine and the remaining two thirds in feces (Wiseman and 
McTavish 1994). Dosage reduction is recommended in patients 
with severe renal failure, since renal clearance of trandolapril 
is directly proportional to creatinine clearance (Danielson et al 
1994). In healthy volunteers, no signiﬁ  cant interactions were 
observed when trandolapril was co-administered with most 
frequently used cardiovascular (CV) drugs including warfarin 
(Wiseman and McTavish 1994; Meyer et al 1995).
Therapeutic use
Patients with LV dysfunction 
after myocardial infarction (MI)
The TRAndolapril Cardiac Evaluation (TRACE) study 
assessed the effect of ACE inhibition with trandolapril on 
mortality (overall and cardiovascular) and cardiovascular 
morbidity in patients surviving an AMI with reduced LV 
function (TRACE 1994). TRACE was a randomized, double-
blind, placebo-controlled study conducted in 27 centers 
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in Denmark. Eligible patients had an AMI conﬁ  rmed by 
elevated cardiac enzymes, electrocardiographic changes, 
and/or chest pain and reduced LV function confirmed 
by an echocardiography-derived wall motion score 
index (WMSI)  1.2. A WMSI  1.2 approximates a left 
ventricular ejection fraction  35% in the nine-segment 
model originally described by Heger et al (1980). Patients 
with residual ischemia and/or clinical heart failure were not 
excluded. Only the following exclusion criteria were used: 
an absolute or relative contraindication or a deﬁ  nite need 
for ACE inhibition; severe, uncontrolled diabetes mellitus; 
hyponatremia ( 125 mmol/L sodium); an elevated serum 
creatinine level (2.3 mg/dL [200 mmol/L]); pregnancy or 
lactation; acute pulmonary embolism; vascular collagen 
disease; non-ischemic obstructive heart disease; unstable 
angina requiring immediate invasive therapy; severe liver 
disease; neutropenia or concurrent immunosuppressive or 
antineoplastic therapy; drug or alcohol abuse; or treatment 
with another investigational drug. Trandolapril or placebo 
was added to conventional therapy 3 to 7 days after AMI 
(mean 4.5 days). Between May 1990 and June 1992, 6674 
patients (7010 infarctions) were screened. A total of 2614 
patients had a wall motion index  1.2; of these, 1749 were 
included, with a follow-up of 24 to 50 months. Overall 1-year 
mortality in the study was 24% (TRACE 1994).
Baseline characteristics showed no signiﬁ  cant differences 
except the use of nitrates, which was higher in the active 
drug group (p   0.005) (Kober et al 1995). Mean age was 
67 years and 70% of the population were males. 47% had 
had an anterior Q wave MI and 21% of patients had a Killip 
class  2 at randomization. The study was done in the early 
1990s with 90% receiving aspirin, 16% β-blockers, 28% 
calcium channel antagonists and around 30% digoxin or 
digitalis (Kober et al 1995).
During the study period, 304 patients (34.7%) in the 
trandolapril group died, compared with 369 (42.3%) 
in the placebo group (p = 0.001) (Kober et al 1995) 
(Figure 2). The relative risk (RR) of death from any cause 
in the trandolapril group, compared with the placebo group, 
was 0.78 (95% conﬁ  dence interval [CI] 0.67–0.91; p = 0.001), 
mostly from cardiovascular causes (226 vs 288 in the tran-
dolapril and placebo groups respectively, RR 0.75, 95% 
CI 0.63–0.89, p = 0.001). Fewer patients died suddenly in 
the trandolapril vs the placebo group (105 vs 133, RR 0.76, 
95% CI 0.59–0.98, p = 0.03). Time to other endpoints such as 
reinfarction and severe heart failure are shown in Figure 3.
Several long term follow-up and secondary analyses 
of the TRACE study have addressed additional aspects of 
trandolapril use after AMI. First, the prognostic importance 
of atrial ﬁ  brillation (AF) development and the impact of 
trandolapril have been studied. Of all patients enrolled (trial 
or registry), sustained or paroxysmal AF or atrial ﬂ  utter (AFL) 
was observed in 1149 patients (19%) during hospitalization 
(Pedersen et al 2006). During follow-up, 1659 patients (34%) 
in the registry died: 482 (50%) patients with AF/AFL and 
1177 (30%) patients without AF/AFL, p   0.001. Sudden 
cardiac death (SCD) occurred in 536, non-SCD occurred in 
725, and 398 died of non-cardiovascular causes (including 
142 unclassiﬁ  able cases). The adjusted risk ratio of AF/AFL 
for total mortality was 1.33 (95% CI 1.19–1.49; p   0.0001), 
1.31 for SCD (95% CI 1.07–1.60, p   0.009) and 1.43 for 
non-SCD (95% CI 1.21–1.70, p   0.0001). Therefore, after 
an AMI, AF/AFL are associated with increased mortality, 
both from SCD and non-SCD (Pedersen et al 2006). In 
the TRACE study, AF developed in only 2.8% of patients 
receiving trandolapril compared with 5.3% in the placebo 
group (p   0.05), even after multivariate analyses (Pedersen 
et al 1999). More recently, ACE inhibition has been shown to 
prevent new-onset AF, facilitate direct current cardioversion 
and maintain sinus rhythm (Kalus et al 2006). A complete 
discussion on this topic is beyond the scope of this article and 
may be found elsewhere (Palardy and Ducharme 2005).
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Figure 2 Cumulative mortality from all causes among patients receiving trandolapril 
or placebo. Reprinted with permission from Kober L, Torp-Pedersen C, Carlsen JE, 
et al 1995. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril 
in patients with left ventricular dysfunction after myocardial infarction. Trandolapril 
Cardiac Evaluation (TRACE) Study Group. N Engl J Med, 333:1670–6. Copyright © 1995 
Massachusetts Medical Society. All rights reserved.Vascular Health and Risk Management 2008:4(6) 1150
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Most of the data on ACE inhibition and heart failure after 
AMI have limited follow-up duration, owing to the nature 
of randomized trials. An extended follow-up from TRACE 
(Buch et al 2005) has been published, focusing on long 
term survival (more than 10 years) and hospital admission 
occurring during and beyond the randomized phase of the 
study. The mortality curves between patients initially allocated 
to trandolapril or placebo started to diverge during the ﬁ  rst 
year, favoring trandolapril, and remained thereafter. The 
Kaplan–Meier estimate of mortality at 10 years was 71.5% 
in the placebo group and 69.5% in the trandolapril group. For 
the entire follow-up, trandolapril signiﬁ  cantly reduced the risk 
of death from any cause compared with placebo (RR 0.89, 
95% CI 0.80–0.99, p = 0.031) (Figure 4), all causes hospital 
admissions (RR 0.92, 95% CI 0.88–0.96, p   0.001) and car-
diac hospitalizations (RR 0.95, 95% CI 0.91–1.00, p = 0.047), 
the majority being for heart failure (Buch et al 2005). These 
data suggest an early beneﬁ  t of ACE inhibition after AMI 
and persistent effects over time, beyond the randomized trial 
duration, a period after which most patients initially allocated 
to placebo will have been switched to an ACE inhibitor.
Diabetic patients with left-
ventricular dysfunction after MI
A growing body of evidence indicates that regulation of the 
rennin–angiotensin system is important for the prevention of 
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Figure 3 Event rates for the secondary end points of death from cardiovascular causes, sudden death, reinfarction and severe or resistant heart failure among patients 
receiving trandolapril or placebo. Reprinted with permission from Kober L, Torp-Pedersen C, Carlsen JE, et al 1995. A clinical trial of the angiotensin-converting-enzyme 
inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med, 333:1670-6. 
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cardiovascular events, not only in hypertensive patients, but 
also in diabetics; they are considered high risk with markedly 
increased mortality after AMI, almost double that of patients 
without diabetes. This excess mortality seems to be related to 
congestive heart failure and reinfarction episodes (Zuanetti 
et al 1993; Granger et al 1993; Malmberg et al 1996; Mak 
et al 1997). ACE inhibition is beneﬁ  cial in these patients, 
mainly through prevention of LV remodeling (Cohn et al 
2000). Other mechanisms have also been suggested such as 
improvement in: ﬁ  brinolytic balance, endothelial function, 
sympatho-vagal balance and glycemic control, in addition to 
preservation of renal function (Gustafsson et al 1999).
A subgroup analysis of diabetics patients enrolled in 
TRACE showed that ACE inhibition with trandolapril is 
beneﬁ  cial in this population. As previously mentioned, diabetic 
patients had a worse prognosis than non-diabetic patients, 
but prognosis was improved with ACE inhibitor treatment, 
with a RR for total mortality of 0.64 (95% CI: 0.45–0.91) 
compared with placebo, after multivariate analysis including 
age, gender, body mass index, smoking, previous MI, 
hypertension, AF, CHF, residual angina and WMSI 
(Gustafsson et al 1999) (Figure 5). Interestingly, in diabetics 
treatment with trandolapril compared to placebo reduced all 
secondary endpoints by approximately 50%. Of particular 
interest was the marked reduction in the progression toward 
severe heart failure with trandolapril (RR = 0.38, 95% CI: 
0.21–0.67). For the non-diabetic patients, only cardiovascular 
death was reduced signiﬁ  cantly with ACE inhibitor treatment 
(RR 0.79, 95% CI 0.66–0.96).
In a small randomized trial of type 2 diabetes patients, 
coronary ﬂ  ow velocity reserve improved after treatment with 
an ACE inhibitor but not with an angiotensin-II receptor 
antagonist, suggesting that ACE inhibition might have 
beneﬁ  cial effects on coronary microangiopathy associated 
with type 2 diabetes (Kawata et al 2006). In an experimental 
model of diabetes, this condition was associated with 
decreased myocardial capillary supply, which was reversed 
by ACE inhibition, but not by endothelin-1 receptor blockade. 
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Figure 5 Cumulative mortality from all causes for patients with (A) and without (B) diabetes receiving trandolapril or placebo. Reprinted with permission from Gustafsson F, 
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Attenuation of cardiac ﬁ  brosis deposition with ACE inhibitor 
was also seen (Gross et al 2004).
The prognostic importance of optimal glycaemia control 
has been recently recognized. Hence the effects on glucose 
metabolism of the beta-blocker atenolol and the ACE inhibitor 
trandolapril were investigated in patients with primary 
hypertension, using a small, randomized, double-blind, paral-
lel-group design. After 48 weeks of treatment, insulin sensi-
tivity was reduced by 23% using atenolol, while it remained 
unchanged with trandolapril (+0.5%, p = 0.0010) (Reneland 
et al 2000). Although interesting, the subject remains highly 
controversial (Petrie et al 2000; New et al 2000). Nevertheless, 
there is additional evidence that ACE inhibitor with trandol-
april improves the progression of diabetic peripheral neuropa-
thy (Malik et al 1998; Stoschitzky 1999; Malik 2000).
ACE inhibition in stable coronary 
artery disease
The concept of vascular protection has been proposed after 
retrospective analysis from both SOLVD and SAVE has 
suggested reduced recurrent MI in HF patients allocated to 
ACE inhibitor compared with placebo. Hence large scale 
trials have been designed to test this hypothesis. The ﬁ  rst two 
trials with ACE inhibitors have been undertaken in high-risk 
patients with either coronary artery disease (CAD) without 
symptomatic heart failure, pre-existing vascular disease, or 
diabetes combined with an additional cardiovascular risk 
factor. In these situations, ACE inhibition with ramipril or 
perindopril leads to reduced rates of the combined endpoint 
of death from cardiovascular causes, acute MI or stroke in 
the Heart Outcomes Prevention Evaluation (HOPE) trial 
(Yusuf et al 2000) or the combined endpoint of cardiovascular 
death, MI, or cardiac arrest in the European Trial on Reduction 
of Cardiac Events with Perindopril in Stable Coronary Artery 
Disease (EUROPA) trial (Fox 2003). These two trials are 
similar and enrolled patients at increased risk of adverse 
cardiovascular events. Although patients with symptomatic 
heart failure were excluded from these trials, there was no 
requirement for LV ejection fraction measurement and the 
brain natriuretic peptide biomarker was not available at that Vascular Health and Risk Management 2008:4(6) 1153
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time. Nevertheless, the concept of vascular protection with 
ACE inhibitor was supported by these studies.
The goal of the Prevention of Events with Angiotensin 
Converting Enzyme Inhibition (PEACE) trial was to test 
whether ACE inhibitor therapy, when added to modern 
conventional therapy, would reduce the rate of non-fatal 
MI, death from cardiovascular causes, or revascularization 
in patients with stable coronary artery disease and normal or 
slightly reduced LV function (Braunwald et al 2004). PEACE 
enrolled patients aged 50 years or older with coronary artery 
disease documented by at least one of the following: MI at 
least 3 months before enrolment; coronary-artery bypass 
grafting or percutaneous transluminal coronary angioplasty 
at least 3 months before enrolment; obstruction of  50% 
of the luminal diameter of at least one native vessel 
on coronary angiography and left ventricular ejection 
fraction  40% on contrast or radionuclide ventriculography 
or echocardiography; a qualitatively normal left ventriculo-
gram; or the absence of LV wall-motion abnormalities on 
echocardiography. Patients hospitalized for angina within 
the preceding 2 months were excluded as well as any other 
unstable cardiac or non-cardiac condition. The original 
endpoint was reduction in cardiovascular death or non-fatal 
MI, and required a sample size of 14,100 patients. Due to 
recruiting difﬁ  culties, this primary endpoint was changed by 
the steering committee, to include coronary revascularization, 
which reduced the sample size to 8100. The original primary 
endpoint became a secondary endpoint. Of the 8290 patients 
who underwent randomization, 4158 were assigned to receive 
trandolapril and 4132 matching placebo. Compliance with the 
target trandolapril dose (4 mg) was 68.4% in the treatment 
group and 77.7% in the placebo group. The median follow-
up was 4.8 years. Baseline characteristics include patients’ 
mean ( ± SD) age of 64 ± 8 years and 18% of patients enrolled 
were women. 55% had a previous MI, 72% had undergone 
at least one coronary-revascularization procedure, and 
17% were known to have diabetes. A quantitative ejection 
fraction was available for 95% of the cohort, with a mean 
value of 58 ± 9%; for the remaining 5%, a two-dimensional 
echocardiogram reported normal LV function by qualitative 
assessment. 70% of patients were using lipid-lowering drugs. 
The average serum cholesterol concentration was 192 mg/dL 
(5 mmol/L) (Braunwald et al 2004). The incidence of the 
new primary endpoint was 22.5% in the placebo group and 
21.9% in the trandolapril group (HR 0.96, 95% CI 0.88–1.06, 
p = 0.43) (Braunwald et al 2004) (Figure 6). Side effects 
leading to discontinuation of the study medication occurred 
in 6.5% of the patients in the placebo group and 14.4% of 
those in the trandolapril group (p   0.001), mainly due to 
cough (39.1% vs 27.5%, p   0.01) and syncope (4.8% vs 
3.9%, p = 0.04), which were higher in the trandolapril group 
(Braunwald et al 2004). Angioedema was reported in 5 
patients in the placebo group (2 were openly taken ACE 
inhibitors) and in 8 patients in the trandolapril group.
Compared with previous studies, patients in the PEACE 
trial were at lower risk of death from cardiovascular causes, 
non-fatal MI or stroke than patients enrolled in the HOPE 
or EUROPA trials, as can be appreciated in Figure 7. 
This might, in part, explain the neutral results of this large 
trial. Moreover, patients in the PEACE trial were more 
aggressively treated (more previous revascularization and 
more intensive management of risk factors) than patients in 
the previous trials. In particular, the level of LDL cholesterol 
and lipid lowering treatment used (statins) are important. 
ACE inhibitors and statins have a common mechanism of 
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action: they both reduce activation of the lectin-like oxidized 
LDL receptor and thus reduce oxidation of LDL cholesterol. 
If the concentration of LDL cholesterol is sufﬁ  ciently low, 
ACE inhibitors may no longer be effective in reducing the 
rate of cardiovascular events (Pitt 2004).
In spite of these neutral results, current guidelines 
recommend ACE inhibition in CAD patients with other 
indications for these agents, such as hypertension, LV systolic 
dysfunction with/without prior MI, symptomatic heart 
failure or diabetes (Anderson et al 2007). In revascularized 
CAD patients treated with aspirin and statins, and no formal 
indication for ACE inhibitor treatment, the beneﬁ  t should 
perhaps be weighed against the cost, risk and side effects.
Patients with hypertension
ACE inhibitors have been used since the 1970s for the 
treatment of hypertension (HTN). Their advantage in this 
population not only lies in secondary beneﬁ  cial effects of 
reduction in levels of angiotensin-II, but also in decreased 
catecholamine levels and vascular remodelling, among others. 
Trandolapril has been approved by the US Food and Drug 
Administration in the US in 1996 and in Canada in 1997 for 
the treatment of patients with mild to moderate hypertension. 
Many controlled clinical trials have found that trandolapril, 
alone or in combination with other antihypertensive agents, 
produces clinically signiﬁ  cant blood pressure (BP) reductions 
and achieves target BP levels in patients with primary HTN 
(Mancia et al 1992; Guller et al 1993; Cesarone et al 1994; 
Omboni et al 1995; Guay 2003; Pepine et al 2003; Tytus 
et al 2007)
TRAIL (The Canadian Study of Trandolapril on Blood 
Pressure in Hypertensive Patients) was a 26-week, prospective, 
open-label, multicenter study in Canadian primary care 
centers (Tytus et al 2007). Subjects with HTN stages I and 
II according to the 7-JNC (Chobanian et al 2003) who were 
treatment naive or whose disease was uncontrolled on current 
ﬁ  rst-line antihypertensive monotherapy, were treated with 
trandolapril alone or in addition to their current regimen. 
Trandolapril was started at 1 mg and was titrated to 2 or 4 mg. 
The purpose of the study was to evaluate the effectiveness of 
escalating-dose regimen of trandolapril in HTN management. 
In the total cohort, 71% of patients reached adequate BP 
control according current guidelines ( 140/90 mmHg in 
subjects with no other risk factors and  130/80 mmHg in 
patients with kidney disease or diabetes) after 2 weeks of 
treatment and 73.4% after 26 weeks. Optimal BP control 
was equally achieved in naive patients as well as in patients 
already treated but with sub-optimal BP control.
INVEST (The INternational VErapamil-Trandolapril 
Study) was a randomized, open label study of 22,576 
hypertensive CAD patients aged 50 years or older, conducted 
from September 1997 to February 2003 at 862 sites 
in 14 countries (Pepine et al 2003). The combined primary 
endpoint was death (all cause), or ﬁ  rst occurrence of non-fatal 
MI or non-fatal stroke. Other endpoints included cardiovascular 
death, angina, adverse reactions, hospitalizations, and blood 
pressure control at 24 months. Patients were randomly 
assigned to verapamil sustained release or atenolol. 
Subsequently, trandolapril (for the calcium channel blocker 
[CCB] group) and hydrochlorothiazide (for the beta blocker 
[BB] group) were added if needed to achieve BP target levels 
according to the 6-JNC guidelines. Trandolapril was also 
recommended when there was a clear clinical indication such 
as for patients with heart failure, diabetes or renal impairment. 
The mean follow-up was 2.7 years. A primary outcome event 
occurred in 9.93% of the patients in the CCB group vs 10.17% 
in the BB group, with a RR of 0.98 (95% CI 0.90–1.06). Two-
year BP control was similar in the two groups, demonstrating 
that the verapamil–trandolapril strategy was as effective as 
the atenolol–hydrochlorothiazide strategy. The INVEST trial 
was designed to have a short follow-up which may explain 
the lack of statistical power to demonstrate a reduction in 
hard endpoints.
A retrospective analysis from TRACE on the subgroup 
of patients with hypertension conﬁ  rmed the worse prognosis 
of HTN after AMI compared with patients without HTN 
(Gustafsson et al 1997). 173 patients (43%) with a medical 
history of hypertension at randomization (the hypertensive 
group) died during follow-up, versus 500 (37%) without 
HTN history. Of note, treatment with trandolapril resulted 
in a profound beneﬁ  cial effect in this population, with a RR 
of death from any cause for the hypertensive group of 0.59 
(95% CI 0.44–0.80) in the trandolapril group compared with 
placebo, versus 0.85 (95% CI 0.72–1.02) for normotensive 
patients allocated to the ACE inhibitor (Gustafsson et al 
1997). The interaction between the diagnosis of HTN and 
the beneﬁ  t of trandolapril treatment was highly signiﬁ  cant 
(p   0.001) (Gustafsson et al 1997).
Prevention of proteinuria
Many trials have shown that not only inadequate diabetes 
control (reﬂ  ected by elevated glycosylated hemoglobin), 
but also hypertension, dyslipidemia, cigarette smoking, 
old age, insulin resistance, male sex, and afro-Caribbean, 
Asian or native American origin are strong risk factors for 
the development of diabetic nephropathy (Gall et al 1991; Vascular Health and Risk Management 2008:4(6) 1155
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Keller et al 1996; Ravid et al 1998). In normal subjects, 
an elevated preglomerular vascular resistance protects the 
glomerular microcirculation from systemic BP variations. 
In patients with diabetic nephropathy, this protective 
mechanism is blunted and vasodilatation of the afferent 
(preglomerular) vessels occurs, permitting the systemic BP 
variation to be transmitted to the glomerular bed. Hence, strict 
BP control is mandatory in these patients in order to avoid 
further glomerular damage. In diabetic nephropathy, typical 
histological progressive changes in the glomerular structure 
can be found, which leads at ﬁ  rst to microalbuminuria, 
followed by selective albuminuria and later on to non-
selective protein excretion with a progressive decline in renal 
function and end-stage renal failure.
Microalbuminuria has been extensively studied as a risk 
factor for cardiovascular outcomes, mostly in patients with 
diabetes mellitus (Sarnak et al 2003). This association has been 
also observed in patients with vascular diseases (Gerstein et al 
2001), electrocardiographic ST-T segment changes (Diercks 
et al 2002) and those with hypertension (Ljungman et al 1996; 
Agewall et al 1997; De Leeuw et al 2002). At ﬁ  rst, it was 
thought that proteinuria reduction and renal protection induced 
by ACE inhibitors were primarily due to vasodilatation of 
the efferent arteriole with subsequent decrease in glomerular 
capillary pressure (Miettinen et al 1996). However, ACE 
inhibitors play an additional role in glomerular function by 
modifying glomerular size and permeability and increasing 
negative electric charge in the glomerular membrane (Amann 
et al 1993, Remuzzi et al 1990).
The MIcroalbuminuria, Cardiovascular, and Renal 
Outcomes in HOPE (MICRO-HOPE) substudy showed 
that ramipril treatment was associated with a decreased risk 
of development of overt nephropathy in patients enrolled 
in HOPE and evidence of microalbuminuria at baseline 
(HOPE Study Investigators 2000). Likewise, the BENEDICT 
(BErgamo NEphrologic DIabetes Complications Tial) 
evaluated whether a combination therapy of ACE inhibitor 
and CCB was better than either class alone or placebo 
in decreasing the progression toward microalbuminuria 
in normoalbuminuric patients with type 2 diabetes and 
hypertension (Ruggenenti et al 2004). In BENEDICT, 
1204 patients were randomized to either a combination of 
trandolapril and verapamil, trandolapril alone, verapamil 
alone or placebo. Median follow-up was 3.6 years. 
A total of 601 subjects received an ACE inhibitor (alone 
or with verapamil) and 603 subjects did not. Persistent 
microalbuminuria, the primary endpoint, was reached in 
35 (5.8%) subjects who received an ACE inhibitor-based 
therapy and in 66 (10.9%) in subjects who did not. This dif-
ference was statistically signiﬁ  cant (p   0.001) even after 
adjustment for site, age, sex, smoking status, diastolic BP 
and log-transformed urinary albumin excretion at baseline 
(Figure 8). At the end of the study, patients in the trandolapril 
group (alone or in combination with verapamil) had a lower 
BP than patients in the verapamil group alone.
The PROCOPA study was designed to compare whether 
the magnitude of proteinuria reduction with different 
classes of anti-hypertensive agents differs, while similar BP 
reduction is achieved (PROCOPA 2002). It was a prospective, 
randomized, double-blind, controlled trial. Inclusion criteria 
included: BP   130/85 mmHg, primary renal disease, 
proteinuria  1 g/day and creatinine clearance  50 mL/min. 
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Figure 8 Kaplan–Meier Curves for the Percentages of Subjects with Microalbuminuria 
during Treatment with or without ACE Inhibitors (Panel A) and with or without 
Non-Dihydropyridine Calcium-Channel Blockers (Panel B). The difference between 
the group that received ACE inhibitor therapy and the group that did not, adjusted 
for prespeciﬁ  ed baseline covariates (see text) was signiﬁ  cant (p   0.001) according 
to the accelerated failure-time model.   The difference between the group that received 
non-dihydropyridine calcium-channel blockers and the group that did not was not 
signiﬁ  cant (p = 0.92). Reprinted with permission from Ruggenenti P, Fassi A, Ilieva AP, 
et al 2004. Preventing microalbuminuria in type 2 diabetes. N Engl J Med, 351:1941–51. 
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After a run-in period, patients were randomized to atenolol, 
trandolapril, verapamil or a combination of verapamil 
and trandolapril for 6 months. There was no statistically 
significant difference in BP control between groups. 
However, a signiﬁ  cant fall in protein urinary excretion 
was obtained in the ACE inhibitor-based strategy (both 
trandolapril/verapamil combination and trandolapril-alone 
groups), suggesting that in spite of adequate and similar 
BP control provided by the four classes of agents, only 
ACE inhibition reduces proteinuria in primary renal dis-
ease. No angiotensin-II receptor blockers were included 
in this trial.
Advantages of trandolapril over 
other ACE inhibitors
Appropriate, recommended and optimal dosage with ACE 
inhibitors is becoming more prominent in cardiovascular 
literature (Furberg and Pitt 2001; Hansen et al 2008). There 
is solid evidence from pharmacokinetic and hard endpoint 
clinical trials for the optimal trandolapril dosage to use. 
Despite the fact that most ACE inhibitors are recommended 
for once-daily administration, only fosinopril, ramipril and 
trandolapril have trough-to-peak effect ratios in excess of 
50% (Song and White 2002). Other ACE inhibitors, such 
as perindopril, have obtained indication for heart failure 
with a dosage of 4 mg daily, but should it be 8 mg or even 
16 mg per day? Current US guidelines for the management 
of chronic heart failure acknowledge this problem and they 
do not establish a precise recommended dosage for enalapril, 
lisinopril or perindopril (Hunt et al 2005). The task force 
for the diagnosis and treatment of chronic heart failure of 
the European Society of Cardiology also leave the clinician 
with this dilemma. Therefore in Europe, only enalapril 
(10 mg twice a day) and trandolapril (4 mg daily) have 
precise recommended evidence-based dosage (Swedberg 
et al 2005).
Conclusion
Trandolapril is a well studied, safe and effective ACE 
inhibitor with clinically convenient pharmacologi-
cal properties. It is widely used in the management of 
cardiovascular disorders in different populations, such as 
patients with hypertension and diabetic patients with coro-
nary artery disease, and especially in the prevention and 
management of proteinuria. Particularly, there is a sound 
evidence-based support for trandolapril 4 mg once a day in 
post-MI patients with LV dysfunction regardless of heart 
failure symptoms.
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